How to transform traditional Chinese medicine enterprises has become a big test

[pharmaceutical network market analysis] a few days ago, the complete version of the national directory of basic medical insurance, industrial injury insurance and maternity insurance drugs in 2019 has been officially implemented In the article, "natural drug development and production" is encouraged, and Chinese medicine is clearly listed as a key support project The industry believes that the traditional Chinese medicine industry is developing in the direction of high quality, the industry reshuffle intensifies, and the leading enterprises will benefit significantly It is reported that step pharmaceutical, the leading enterprise in the industry, is seizing the opportunity and has formulated three strategic layouts for transformation The first is to transform from marketing driven to product driven, to technology-based companies; the second is to transform from Chinese patent medicine to the whole industry of bio medicine, chemical medicine, medical devices, Internet medicine, etc.; the third is to transform from China's localization to globalization, and steadily realize the strategic planning of Bio pharmacy In fact, for most traditional Chinese medicine enterprises, with the strengthening of series management and control, the performance declines significantly, and the transformation has become the industry trend Among them, innovative medicine and great health have become the transformation and layout of many traditional Chinese medicine enterprises For example, in November 2019, HongRi pharmaceutical announced that it had received the notice of clinical trial from the drug regulatory bureau, saying that the innovative drug, the oral PD-L1 drug, emdifen tablet, it was in line with the relevant requirements of the drug clinical trial review and approval, was approved to carry out the clinical trial of solid tumor, and will carry out the clinical trial in the near future According to the public information, HongRi pharmaceutical is a pharmaceutical enterprise founded by traditional Chinese medicine, whose main product is Xuebijing injection, which has been greatly impacted by the policy in recent years The industry believes that this may be the layout of the transformation of HongRi pharmaceutical industry to the direction of innovative drugs In Daxing District, Beijing, Jiuzhitang Meike has built a production site of allogeneic stem cells in line with the cGMP standards of the United States and the European Union for the production of human bone marrow mesenchymal stem cells and neural stem cells At the same time, Jiuzhitang Meike (Beijing) cell technology Co., Ltd invested by the company's M & A fund and Kazakhstan LLP "altaco-xxi" company in Jiuzhitang - altaco stem cell International Medical Center in Horgos have been officially operated since September 7, 2019 The company also plans to carry out stem cell clinical research on nervous system and cardiovascular and cerebrovascular diseases based on the results of clinical trials conducted by stemedica in the United States, so as to promote the early listing of stem cell drugs in China In addition to these pharmaceutical enterprises, there are many traditional Chinese medicine enterprises, such as Tianshili, Yunnan Baiyao, Tongrentang, and other listed pharmaceutical enterprises, who are representatives of them, to lay out bio pharmaceuticals in advance or expand their business to the large health field According to the industry, due to the special properties of traditional Chinese medicine, it will become a trend for traditional Chinese medicine enterprises to transform the pipeline reserve of biological medicine research and development However, as innovative drugs are different from traditional Chinese medicine and require more stringent technical level, it also means that traditional Chinese medicine enterprises face high risk and market test period in the process of transformation For example, in terms of the performance of the secondary market, the stock price of HongRi pharmaceutical mentioned above has not increased significantly Some insiders said that they need to see the follow-up progress of the project and the published clinical data However, Jiuzhitang used to be mainly engaged in R & D, production and sales of proprietary Chinese medicine The industry believes that it may take some time to observe the real shift to stem cell drug development that has little to do with the main business It can be seen that traditional Chinese medicine enterprises are still facing a test in the process of transformation In addition, at present, with the promotion of policies such as centralized mining, DRGs, and proportion of drugs, the industry believes that even though some provinces and cities have relaxed the difficulty of Western medicine's qualification to open traditional Chinese medicine to a certain extent, they will still be subject to strict restrictions on auxiliary drugs and traditional Chinese medicine Therefore, under the current policy and environment trend, it is expected that the transformation period left for traditional Chinese medicine enterprises will not be long.